Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]
Lung Cancer. 2019 Oct:136:158.
doi: 10.1016/j.lungcan.2019.08.017.
Epub 2019 Aug 21.
1 Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3 Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
4 Department of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5 Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: vsubbiah@mdanderson.org.